"2 Peanut Patch to Treat Allergy in the Works"
The daily application of a skin patch (Viaskin, DBV Technologies) that releases peanut protein is effective and safe for peanut immunotherapy, according to the largest clinical trial in peanut allergy desensitization to date. The epicutaneous immunotherapy could be "the first FDA-approved form of therapy for peanut allergy," said Hugh Sampson, MD, from the Jaffe Food Allergy Institute at the Kravis Children's Hospital at Mount Sinai in New York City. Dr. Sampson presented results from the Viaskin Peanut's Efficacy and Safety (VIPES) study here at the American Academy of Allergy, Asthma & Immunology 2015 during a late-breaking abstract session. Learn more.

Mount Sinai Establishes Steven S. Elbaum Family Center for Caregiving
May 20, 2025 View All Press Releases
Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State
May 20, 2025 View All Press Releases
Mount Sinai Launches AI Small Molecule Drug Discovery Center
Apr 02, 2025 View All Press Releases